Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis

24Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Background and objectives: Idiopathic pulmonary fibrosis (IPF) has a particularly poor prognosis, and most IPF-related deaths are due to acute exacerbation (AE) of this condition. Few reports about biomarkers to predict prognosis of AE-IPF have been published since the release of the new AE-IPF criteria in 2016. The present study investigated relationships between serological markers and in-hospital mortality after the onset of AE-IPF. Methods: Demographic, serological, and imaging data from patients hospitalized at the Maebashi Red Cross Hospital (Gunma, Japan) between 1 January 2013, and 31 December 2017, were retrospectively reviewed. Subjects fulfilling the diagnostic criteria for AE-IPF were divided into those who survived or died; statistical analysis of risk factors was performed using data from these two groups. Results: Diagnostic criteria for AE-IPF were fulfilled by 84 patients (59 males (70.2%)), with a median age of 78 years (range, 56–95 years). IPF was diagnosed before hospitalization in 50 (59.5%) patients and 38 (45.2%) died in hospital. Among the serological markers at hospitalization in the deceased group, C-reactive protein (CRP) was significantly higher than in the survivor group (p = 0.002), while total serum protein (p = 0.031), albumin (p = 0.047) and total cholesterol (p = 0.039) were significantly lower. Cox hazard analysis of factors predicting mortality, corrected for age, sex and BMI, revealed the following: CRP (hazard ratio (HR) 1.080 (95% confidence interval (CI) 1.022–1.141); p = 0.006), LDH (HR 1.003 (95% CI 1.000–1.006); p = 0.037), and total cholesterol (HR 0.985 (95% CI 0.972–0.997); p = 0.018). Conclusions: Our data suggest that CRP, LDH, and total cholesterol may be biomarkers predicting mortality in patients with AE-IPF. However, only prospective controlled studies can confirm or not our observation as a generalizable one.

References Powered by Scopus

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

3571Citations
N/AReaders
Get full text

Acute exacerbation of idiopathic pulmonary fibrosis an international working group report

1068Citations
N/AReaders
Get full text

Acute exacerbations of idiopathic pulmonary fibrosis

1022Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis

235Citations
N/AReaders
Get full text

Differential discontinuation profiles between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis

38Citations
N/AReaders
Get full text

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

25Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hachisu, Y., Murata, K., Takei, K., Tsuchiya, T., Tsurumaki, H., Koga, Y., … Hisada, T. (2019). Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis. Medicina (Lithuania), 55(5). https://doi.org/10.3390/medicina55050132

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

100%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

83%

Pharmacology, Toxicology and Pharmaceut... 1

17%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free